Emerging data suggest Retatrutide , a dual stimulator targeting both GLP-1 and glucose-dependent insulinotropic polypeptide , may provide a promising development for weight loss . Early patient trials https://socialstrategie.com/story7205953/the-retatru-tide-substance-a-advancement-in-body-control